不同剂量阿托伐他汀对慢性硬膜下血肿的疗效及安全性评价

发布时间：2018-03-30 02:02

本文选题：阿托伐他汀　切入点：慢性硬膜下血肿　出处：《中国药房》2017年05期

【摘要】：目的:观察不同剂量的阿托伐他汀对慢性硬膜下血肿(CSDH)患者的临床疗效和安全性。方法:选择2013年6月-2015年5月我院CSDH患者128例,按照随机数字表法分为观察组(n=62)和对照组(n=66)。所有患者均给予常规的脑细胞营养治疗;对照组患者给予阿托伐他汀钙片20 mg,po,qd;观察组患者给予阿托伐他汀钙片40 mg,po,qd。两组患者均连续治疗6个月。观察两组患者的临床疗效、神经功能缺损评分标准(CSS)及日常生活能力量表(ADL)评分、血肿量和血清炎症因子[超敏C反应蛋白(hs-CRP)、基质金属蛋白酶9(MMP-9)、白细胞介素6(IL-6)和肿瘤坏死因子α(TNF-α)]水平,记录治疗过程中的不良反应及治疗后6个月内的复发率。结果:观察组患者脱落2例,对照组患者脱落6例,最终纳入统计的合格病例为120例,两组各60例。观察组患者总有效率(88.3%)明显优于对照组(73.3%),差异有统计学意义(P0.05)。治疗后1、3、6个月,两组患者CSS评分、血肿量和血清hs-CRP、MMP-9、IL-6、TNF-α水平明显降低,ADL评分明显升高,且观察组患者上述指标改善程度明显优于对照组,差异均有统计学意义(P0.05)。两组患者各项不良反应的发生率比较,差异均无统计学意义(P0.05)。对照组患者的复发率(13.3%)明显高于观察组(3.3%),差异有统计学意义(P0.05)。结论:阿托伐他汀40 mg的日剂量对CSDH患者的临床疗效更好、复发率更低,且安全性良好。
[Abstract]:Objective: to observe the clinical efficacy and safety of different doses of Atto vastatin in patients with chronic subdural hematoma. Methods: 128 patients with CSDH from June 2013 to May 2015 were enrolled in this study. According to the random number table method, the patients were divided into two groups: the observation group (n = 62) and the control group (n = 66). All the patients were given routine brain cell nutrition therapy. The patients in the control group were treated with calcareous tablets of Atto vastatin 20 mg / kg poqd, and those in the observation group were treated with Atto calcareous tablets of 40 mg / kg poqd. The two groups were treated continuously for 6 months. The clinical efficacy of the two groups was observed. Neurologic impairment scale (CSS) and activity of Daily living scale (ADL), hematoma volume and serum inflammatory factors (hypersensitive C-reactive protein hs-CRPU, matrix metalloproteinase-9 (MMP-9), interleukin-6 (IL-6) and tumor necrosis factor- 伪 (TNF- 伪)) were measured. Results: there were 2 cases in the observation group and 6 cases in the control group. There were 60 cases in each group. The total effective rate in the observation group was significantly higher than that in the control group (73.3%), the difference was statistically significant (P 0.05). The CSS score, hematoma volume and serum hs-CRPnMMP-9 / IL-6 / TNF- 伪 level in the two groups were significantly lower than those in the control group (P < 0.05), and the scores of CSS, hematoma and serum hs-CRP / MMP-9 / IL-6 / TNF- 伪 were significantly higher in the observation group than in the control group (P < 0.05). The improvement of the above indexes in the observation group was significantly better than that in the control group, and the difference was statistically significant (P 0.05). The incidence of adverse reactions in the two groups was higher than that in the control group. The recurrence rate of the control group was significantly higher than that of the observation group (P 0.05). Conclusion: the daily dose of Atto vastatin 40 mg is more effective, the recurrence rate is lower, and the safety is good in the CSDH patients. [WT5HZ] [WT5 "HZ] [WT5" HZ] [WT5BZ] the recurrence rate of the patients in the control group is significantly higher than that in the control group, and the difference is statistically significant (P 0.05).
【作者单位】：成都市第六人民医院神经外科;崇州市人民医院神经外科;
【分类号】：R651.15

【参考文献】